Literature DB >> 21046484

Is plasma 25(OH) D related to adipokines, inflammatory cytokines and insulin resistance in both a healthy and morbidly obese population?

Núria Vilarrasa1, Joan Vendrell, Javier Maravall, Iñaki Elío, Esther Solano, Patricia San José, Isabel García, Núria Virgili, Juan Soler, José Manuel Gómez.   

Abstract

To analyse in a cohort of healthy subjects and in a group of morbidly obese patients, we studied the association amongst 25(OH) D and plasma concentrations of adipocytokines, inflammatory cytokines and insulin resistance. We also aimed to determine whether vitamin D-deficient patients showed a greater inflammatory profile. In the observational study that the authors conducted, plasma concentrations of 25(OH) D, leptin, resistin, adiponectin and interleukine-18 were determined in 134 healthy men and 127 women. In the population consisting of 44 patients with morbid obesity, plasma concentrations of 25(OH) D, leptin, resistin, adiponectin, interleukine-18, soluble tumor necrosis factor receptors 1 and 2 and C-reactive protein were analysed. In the healthy population, plasma 25(OH) D showed a negative correlation with body mass index, body fat, waist, hip circumference and with leptin. However, no significant associations were found amongst 25(OH) D and plasma concentrations of resistin, adiponectin or interleukine-18. Patients with vitamin D deficiency showed higher body mass index, fat mass percentage and higher leptin concentrations compared with subjects with normal 25(OH) D concentrations. In the morbidly obese subjects, 25(OH) D did not correlate with leptin, resistin, adiponectin, interleukine-18, soluble tumor necrosis factor receptors 1 and 2 or with C-reactive protein. In patients with morbid obesity, no differences were found in adipokines and inflammatory cytokines concentrations regarding 25(OH) D status. No associations were found either between 25(OH) D and plasma glucose and insulin resistance or with lipid profile. Plasma 25(OH) D concentrations are associated with adiposity markers but not with adipocytokines implicated in inflammation. This lack of association does not support a major role of 25(OH) D in the pro-inflammatory environment observed in morbidly obese subjects. In addition, subjects with vitamin D deficiency are not characterized by a greater inflammatory state.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21046484     DOI: 10.1007/s12020-010-9379-4

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  53 in total

1.  High prevalence of hypovitaminosis D in female type 2 diabetic population.

Authors:  G Isaia; R Giorgino; S Adami
Journal:  Diabetes Care       Date:  2001-08       Impact factor: 19.112

Review 2.  Vitamin D deficiency.

Authors:  Michael F Holick
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

3.  Resistin, central obesity, and type 2 diabetes.

Authors:  C L McTernan; P G McTernan; A L Harte; P L Levick; A H Barnett; S Kumar
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

4.  No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects.

Authors:  Rolf Jorde; Monica Sneve; Peter A Torjesen; Yngve Figenschau; Lasse G Gøransson; Roald Omdal
Journal:  Cytokine       Date:  2010-02-01       Impact factor: 3.861

Review 5.  Interleukin-18, a proinflammatory cytokine.

Authors:  C A Dinarello
Journal:  Eur Cytokine Netw       Date:  2000-09       Impact factor: 2.737

6.  Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: the effect on serum IL-1 and IL-6 levels and bone mineral density.

Authors:  Süleyman Türk; Mehmet Akbulut; Alaattin Yildiz; Mehmet Gürbilek; Said Gönen; Zeki Tombul; Mehdi Yeksan
Journal:  Nephron       Date:  2002-02       Impact factor: 2.847

Review 7.  The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis.

Authors:  Anastassios G Pittas; Joseph Lau; Frank B Hu; Bess Dawson-Hughes
Journal:  J Clin Endocrinol Metab       Date:  2007-03-27       Impact factor: 5.958

8.  The effect of weight loss on serum concentrations of nitric oxide, TNF-alpha and soluble TNF-alpha receptors.

Authors:  Magdalena Olszanecka-Glinianowicz; Barbara Zahorska-Markiewicz; Joanna Janowska
Journal:  Endokrynol Pol       Date:  2006 Sep-Oct       Impact factor: 1.582

9.  Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers.

Authors:  Armin Zittermann; Sabine Frisch; Heiner K Berthold; Christian Götting; Joachim Kuhn; Knut Kleesiek; Peter Stehle; Heinrich Koertke; Reiner Koerfer
Journal:  Am J Clin Nutr       Date:  2009-03-25       Impact factor: 7.045

Review 10.  Role of vitamin D in the pathogenesis of type 2 diabetes mellitus.

Authors:  X Palomer; J M González-Clemente; F Blanco-Vaca; D Mauricio
Journal:  Diabetes Obes Metab       Date:  2008-03       Impact factor: 6.577

View more
  39 in total

1.  Investigating the causal effect of vitamin D on serum adiponectin using a Mendelian randomization approach.

Authors:  L L N Husemoen; T Skaaby; T Martinussen; T Jørgensen; B H Thuesen; C Kistorp; J Jeppesen; J P Thyssen; M Meldgaard; P B Szecsi; M Fenger; A Linneberg
Journal:  Eur J Clin Nutr       Date:  2013-11-13       Impact factor: 4.016

2.  Comparative efficacy and safety of different doses of ergocalciferol supplementation in patients with metabolic syndrome.

Authors:  Nakarin Sansanayudh; Supakit Wongwiwatthananukit; Nongluk Phetkrajaysang; Sarinee Krittiyanunt
Journal:  Int J Clin Pharm       Date:  2014-05-23

3.  Factors associated with inflammation markers, a cross-sectional analysis.

Authors:  Tess V Clendenen; Karen L Koenig; Alan A Arslan; Annekatrin Lukanova; Franco Berrino; Yian Gu; Goran Hallmans; Annika Idahl; Vittorio Krogh; Anna E Lokshin; Eva Lundin; Paola Muti; Adele Marrangoni; Brian M Nolen; Nina Ohlson; Roy E Shore; Sabina Sieri; Anne Zeleniuch-Jacquotte
Journal:  Cytokine       Date:  2011-10-19       Impact factor: 3.861

4.  Relationships between circulating 25(OH) vitamin D, leptin levels and visceral adipose tissue volume: results from a 1-year lifestyle intervention program in men with visceral obesity.

Authors:  Anne Gangloff; Jean Bergeron; Isabelle Lemieux; Angelo Tremblay; Paul Poirier; Natalie Alméras; Jean-Pierre Després
Journal:  Int J Obes (Lond)       Date:  2019-03-29       Impact factor: 5.095

5.  Vitamin D deficiency in patients with Graves' disease: probably something more than a casual association.

Authors:  Mario Rotondi; Luca Chiovato
Journal:  Endocrine       Date:  2012-08-25       Impact factor: 3.633

6.  The relation of serum 25-hydroxyvitamin-D levels with severity of obstructive sleep apnea and glucose metabolism abnormalities.

Authors:  N Colak Bozkurt; E Cakal; M Sahin; E Cakir Ozkaya; H Firat; T Delibasi
Journal:  Endocrine       Date:  2012-01-14       Impact factor: 3.633

7.  Effects of vitamin D(2) supplementation on insulin sensitivity and metabolic parameters in metabolic syndrome patients.

Authors:  S Wongwiwatthananukit; N Sansanayudh; N Phetkrajaysang; S Krittiyanunt
Journal:  J Endocrinol Invest       Date:  2013-02-04       Impact factor: 4.256

Review 8.  Vitamin D and serum leptin: a systematic review and meta-analysis of observational studies and randomized controlled trials.

Authors:  M Hajimohammadi; S Shab-Bidar; T R Neyestani
Journal:  Eur J Clin Nutr       Date:  2016-12-14       Impact factor: 4.016

9.  Negative association between trunk fat, insulin resistance and skeleton in obese women.

Authors:  Emanuela A Greco; Davide Francomano; Rachele Fornari; Chiara Marocco; Carla Lubrano; Vincenza Papa; Francesca Wannenes; Luigi Di Luigi; Lorenzo M Donini; Andrea Lenzi; Antonio Aversa; Silvia Migliaccio
Journal:  World J Diabetes       Date:  2013-04-15

10.  Serum 25-hydroxyvitamin D, parathyroid hormone, and their association with metabolic syndrome in Chinese.

Authors:  Li-Hua Li; Xue-Yan Yin; Chao-Yong Yao; Xue-Chuang Zhu; Xin-Hua Wu
Journal:  Endocrine       Date:  2013-01-23       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.